<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">38083997</PMID><DateCompleted><Year>2024</Year><Month>08</Month><Day>07</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>24</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1365-2362</ISSN><JournalIssue CitedMedium="Internet"><Volume>54</Volume><Issue>4</Issue><PubDate><Year>2024</Year><Month>Apr</Month></PubDate></JournalIssue><Title>European journal of clinical investigation</Title><ISOAbbreviation>Eur J Clin Invest</ISOAbbreviation></Journal><ArticleTitle>Serological markers and long COVID-A rapid systematic review.</ArticleTitle><Pagination><StartPage>e14149</StartPage><MedlinePgn>e14149</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/eci.14149</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Long COVID is highly heterogeneous, often debilitating, and may last for years after infection. The aetiology of long COVID remains uncertain. Examination of potential serological markers of long COVID, accounting for clinical covariates, may yield emergent pathophysiological insights.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">In adherence to PRISMA guidelines, we carried out a rapid review of the literature. We searched Medline and Embase for primary observational studies that compared IgG response in individuals who experienced COVID-19 symptoms persisting &#x2265;12&#x2009;weeks post-infection with those who did not. We examined relationships between serological markers and long COVID status and investigated sources of inter-study variability, such as severity of acute illness, long COVID symptoms assessed and target antigen(s).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Of 8018 unique records, we identified 29 as being eligible for inclusion in synthesis. Definitions of long COVID varied. In studies that reported anti-nucleocapsid (N) IgG (n&#x2009;=&#x2009;10 studies; n&#x2009;=&#x2009;989 participants in aggregate), full or partial anti-Spike IgG (i.e. the whole trimer, S1 or S2 subgroups, or receptor binding domain, n&#x2009;=&#x2009;19 studies; n&#x2009;=&#x2009;2606 participants), or neutralizing response (n&#x2009;=&#x2009;7 studies; n&#x2009;=&#x2009;1123 participants), we did not find strong evidence to support any difference in serological markers between groups with and without persisting symptoms. However, most studies did not account for severity or level of care required during acute illness, and other potential confounders.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Pooling of studies would enable more robust exploration of clinical and serological predictors among diverse populations. However, substantial inter-study variations hamper comparability. Standardized reporting practices would improve the quality, consistency and comprehension of study findings.</AbstractText><CopyrightInformation>&#xa9; 2023 The Authors. European Journal of Clinical Investigation published by John Wiley &amp; Sons Ltd on behalf of Stichting European Society for Clinical Investigation Journal Foundation.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Collins</LastName><ForeName>Erin</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0002-4209-1786</Identifier><AffiliationInfo><Affiliation>Faculty of Medicine, School of Epidemiology and Public Health, University of Ottawa, Ottawa, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Philippe</LastName><ForeName>Elizabeth</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, School of Epidemiology and Public Health, University of Ottawa, Ottawa, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gravel</LastName><ForeName>Christopher A</ForeName><Initials>CA</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, School of Epidemiology and Public Health, University of Ottawa, Ottawa, Ontario, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Mathematics and Statistics, University of Ottawa, Ottawa, Ontario, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, Quebec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hawken</LastName><ForeName>Steven</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, School of Epidemiology and Public Health, University of Ottawa, Ottawa, Ontario, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Epidemiology, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Langlois</LastName><ForeName>Marc-Andr&#xe9;</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, Ontario, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Coronavirus Variants Rapid Response Network (CoVaRR-Net), Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Infection, Immunity and Inflammation (CI3), University of Ottawa, Ottawa, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Little</LastName><ForeName>Julian</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, School of Epidemiology and Public Health, University of Ottawa, Ottawa, Ontario, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Epidemiology, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Coronavirus Variants Rapid Response Network (CoVaRR-Net), Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Knowledge Synthesis and Application Unit (KSAU), University of Ottawa, Ottawa, Ontario, Canada.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>CIHR</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D000078182">Systematic Review</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>12</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Eur J Clin Invest</MedlineTA><NlmUniqueID>0245331</NlmUniqueID><ISSNLinking>0014-2972</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007074">Immunoglobulin G</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064370">Spike Glycoprotein, Coronavirus</NameOfSubstance></Chemical></ChemicalList><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007074" MajorTopicYN="Y">Immunoglobulin G</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="Y">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D064370" MajorTopicYN="N">Spike Glycoprotein, Coronavirus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Long COVID</Keyword><Keyword MajorTopicYN="N">Post Acute COVID</Keyword><Keyword MajorTopicYN="N">Post-COVID-19 Syndrome</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">antibodies</Keyword><Keyword MajorTopicYN="N">serology</Keyword><Keyword MajorTopicYN="N">systematic review</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>11</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>11</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>11</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>3</Month><Day>13</Day><Hour>6</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>12</Month><Day>12</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>12</Month><Day>12</Day><Hour>2</Hour><Minute>36</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38083997</ArticleId><ArticleId IdType="doi">10.1111/eci.14149</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>World Health Organization. Post COVID-19 Condition. https://www.who.int/teams/health-care-readiness/post-covid-19-condition</Citation></Reference><Reference><Citation>Public Health Agency of Canada. Post-COVID-19 condition (long COVID). 2021 https://www.canada.ca/en/public-health/services/diseases/2019-novel-coronavirus-infection/symptoms/post-covid-19-condition.html</Citation></Reference><Reference><Citation>Post COVID-19 Condition in Canada. What we know, what we don't know, and a framework for action. 2023 https://science.gc.ca/site/science/en/office-chief-science-advisor/initiatives-covid-19/post-covid-19-condition-canada-what-we-know-what-we-dont-know-and-framework-action</Citation></Reference><Reference><Citation>COVID-19: Evaluation and management of adults with persistent symptoms following acute illness (&#x201c;Long COVID&#x201d;) - UpToDate. 2023. https://www.uptodate.com/contents/covid-19-evaluation-and-management-of-adults-with-persistent-symptoms-following-acute-illness-long-covid</Citation></Reference><Reference><Citation>Spiers N. Reassessment of persistent symptoms, self-reported COVID-19 infection and SARS-CoV-2 serology in the SAPRIS-SERO cohort: identifying possible sub-syndromes of long Covid. medRxiv. 2022. doi:10.1101/2022.02.25.22271499</Citation></Reference><Reference><Citation>Yong SJ, Liu S. Proposed subtypes of post-COVID-19 syndrome (or long-COVID) and their respective potential therapies. Rev Med Virol. 2022;32(4):e2315. doi:10.1002/rmv.2315</Citation></Reference><Reference><Citation>Turner S, Khan MA, Putrino D, Woodcock A, Kell DB, Pretorius E. Long COVID: pathophysiological factors and abnormalities of coagulation. Trends Endocrinol Metab. 2023;34(6):321-344. doi:10.1016/j.tem.2023.03.002</Citation></Reference><Reference><Citation>O'Mahoney LL, Routen A, Gillies C, et&#xa0;al. The prevalence and long-term health effects of long Covid among hospitalised and non-hospitalised populations: a systematic review and meta-analysis. eClinicalMedicine. 2023;55:101762. doi:10.1016/j.eclinm.2022.101762</Citation></Reference><Reference><Citation>Ballouz T, Menges D, Anagnostopoulos A, et&#xa0;al. Recovery and symptom trajectories up to two years after SARS-CoV-2 infection: population based, longitudinal cohort study. BMJ. 2023;381:e074425. doi:10.1136/bmj-2022-074425</Citation></Reference><Reference><Citation>Kim Y, Bae S, Chang HH, Kim SW. Long COVID prevalence and impact on quality of life 2&#x2009;years after acute COVID-19. Sci Rep. 2023;13(1):11207. doi:10.1038/s41598-023-36995-4</Citation></Reference><Reference><Citation>Gualano MR, Rossi MF, Borrelli I, et&#xa0;al. Returning to work and the impact of post COVID-19 condition: a systematic review. Work. 2022;73(2):405-413. doi:10.3233/WOR-220103</Citation></Reference><Reference><Citation>Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol. 2023;21(3):133-146. doi:10.1038/s41579-022-00846-2</Citation></Reference><Reference><Citation>Faghy MA, Maden-Wilkinson T, Arena R, et&#xa0;al. COVID-19 patients require multi-disciplinary rehabilitation approaches to address persisting symptom profiles and restore pre-COVID quality of life. Expert Rev Respir Med. 2022;16:595-600. doi:10.1080/17476348.2022.2063843</Citation></Reference><Reference><Citation>Yong SJ, Halim A, Halim M, et&#xa0;al. Inflammatory and vascular biomarkers in post-COVID-19 syndrome: a systematic review and meta-analysis of over 20 biomarkers. Rev Med Virol. 2023;33(2):e2424. doi:10.1002/rmv.2424</Citation></Reference><Reference><Citation>Boaventura P, Macedo S, Ribeiro F, Jaconiano S, Soares P. Post-COVID-19 condition: where are we now? Life. 2022;12(4):517. doi:10.3390/life12040517</Citation></Reference><Reference><Citation>Mantovani A, Morrone MC, Patrono C, et&#xa0;al. Long Covid: where we stand and challenges ahead. Cell Death Differ. 2022;29(10):1891-1900. doi:10.1038/s41418-022-01052-6</Citation></Reference><Reference><Citation>Altmann DM, Whettlock EM, Liu S, Arachchillage DJ, Boyton RJ. The immunology of long COVID. Nat Rev Immunol. 2023;23:618-634. doi:10.1038/s41577-023-00904-7</Citation></Reference><Reference><Citation>Sudre CH, Murray B, Varsavsky T, et&#xa0;al. Attributes and predictors of long COVID. Nat Med. 2021;27(4):626-631. doi:10.1038/s41591-021-01292-y</Citation></Reference><Reference><Citation>Sarri G, Liu W, Zabotka L, et&#xa0;al. Prognostic factors of COVID-19: an umbrella review endorsed by the International Society for Pharmacoepidemiology. Clin Pharmacol Ther. 2023;114:604-613. doi:10.1002/cpt.2977</Citation></Reference><Reference><Citation>Tsampasian V, Elghazaly H, Chattopadhyay R, et&#xa0;al. Risk factors associated with Post-COVID-19 condition: a systematic review and meta-analysis. JAMA Intern Med. 2023;183:566-580. doi:10.1001/jamainternmed.2023.0750</Citation></Reference><Reference><Citation>Chen B, Julg B, Mohandas S, Bradfute SB, Force RMPT. Viral persistence, reactivation, and mechanisms of long COVID. Elife. 2023;12:e86015. doi:10.7554/eLife.86015</Citation></Reference><Reference><Citation>Tsuchida T, Hirose M, Inoue Y, Kunishima H, Otsubo T, Matsuda T. Relationship between changes in symptoms and antibody titers after a single vaccination in patients with long COVID. J Med Virol. 2022;94(7):3416-3420. doi:10.1002/jmv.27689</Citation></Reference><Reference><Citation>Kervevan J, Staropoli I, Slama D, et&#xa0;al. Divergent adaptive immune responses define two types of long COVID. Front Immunol. 2023;14:1221961. doi:10.3389/fimmu.2023.1221961</Citation></Reference><Reference><Citation>Opsteen S, Files JK, Fram T, Erdmann N. The role of immune activation and antigen persistence in acute and long COVID. J Invest Med 2023;71(5):545. doi:10.1177/10815589231158041, 562</Citation></Reference><Reference><Citation>Joung S, Weber B, Wu M, et&#xa0;al. Serological response to vaccination in post-acute sequelae of COVID. BMC Infect Dis. 2023;23(1):97. doi:10.1186/s12879-023-08060-y</Citation></Reference><Reference><Citation>Swank Z, Senussi Y, Manickas-Hill Z, et&#xa0;al. Persistent circulating severe acute respiratory syndrome coronavirus 2 spike is associated with Post-acute coronavirus disease 2019 sequelae. Clin Infect Dis. 2023;76(3):e487-e490. doi:10.1093/cid/ciac722</Citation></Reference><Reference><Citation>Klein J, Wood J, Jaycox J, et&#xa0;al. Distinguishing features of long COVID identified through immune profiling. medRxiv. 2022. doi:10.1101/2022.08.09.22278592</Citation></Reference><Reference><Citation>Garc&#xed;a-Abell&#xe1;n J, Fern&#xe1;ndez M, Padilla S, et&#xa0;al. Immunologic phenotype of patients with long-COVID syndrome of 1-year duration. Front Immunol. 2022;13:920627. doi:10.3389/fimmu.2022.920627</Citation></Reference><Reference><Citation>Cervia C, Zurbuchen Y, Taeschler P, et&#xa0;al. Immunoglobulin signature predicts risk of post-acute COVID-19 syndrome. Nat Commun. 2022;13(1):446. doi:10.1038/s41467-021-27797-1</Citation></Reference><Reference><Citation>Varnai R, Molnar T, Zavori L, et&#xa0;al. Serum level of anti-nucleocapsid, but not anti-spike antibody, is associated with improvement of long COVID symptoms. Vaccine. 2022;10(2):165. doi:10.3390/vaccines10020165</Citation></Reference><Reference><Citation>Haslam A, Prasad V. Comparability of control and comparison groups in studies assessing long COVID. Am J Med. 2023. doi:10.1016/j.amjmed.2023.01.005</Citation></Reference><Reference><Citation>Du M, Ma Y, Deng J, Liu M, Liu J. Comparison of long COVID-19 caused by different SARS-CoV-2 strains: a systematic review and meta-analysis. Int J Environ Res Public Health. 2022;19(23):16010. doi:10.3390/ijerph192316010</Citation></Reference><Reference><Citation>Antonelli M, Pujol JC, Spector TD, Ourselin S, Steves CJ. Risk of long COVID associated with delta versus omicron variants of SARS-CoV-2. Lancet. 2022;399(10343):2263-2264. doi:10.1016/S0140-6736(22)00941-2</Citation></Reference><Reference><Citation>Spinicci M, Graziani L, Tilli M, et&#xa0;al. Infection with SARS-CoV-2 variants is associated with different long COVID phenotypes. Viruses. 2022;14(11):2367. doi:10.3390/v14112367</Citation></Reference><Reference><Citation>Notarte KI, Catahay JA, Velasco JV, et&#xa0;al. Impact of COVID-19 vaccination on the risk of developing long-COVID and on existing long-COVID symptoms: a systematic review. eClinicalMedicine. 2022;53:101624. doi:10.1016/j.eclinm.2022.101624</Citation></Reference><Reference><Citation>Byambasuren O, Stehlik P, Clark J, Alcorn K, Glasziou P. Effect of covid-19 vaccination on long covid: systematic review. BMJ Med. 2023;2(1):e000385. doi:10.1136/bmjmed-2022-000385</Citation></Reference><Reference><Citation>Rapid Reviews Methods Group|Cochrane Methods. 2016. https://methods.cochrane.org/news/rapid-reviews-methods-group</Citation></Reference><Reference><Citation>Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;8:339-341. doi:10.1136/bmj.b2535</Citation></Reference><Reference><Citation>Our World in Data. SARS-CoV-2 variants in analyzed sequences. https://ourworldindata.org/grapher/covid-variants-area</Citation></Reference><Reference><Citation>Johns Hopkins Coronavirus Resource Center. 2023 https://coronavirus.jhu.edu/vaccines/international</Citation></Reference><Reference><Citation>Wells GA, Shea B, O'Connell D, et&#xa0;al. The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomized Studies in Meta-Analysis. 2011 https://www.ohri.ca/programs/clinical_epidemiology/oxford.asp</Citation></Reference><Reference><Citation>Bilich T, Nelde A, Heitmann JS, et&#xa0;al. T cell and antibody kinetics delineate SARS-CoV-2 peptides mediating long-term immune responses in COVID-19 convalescent individuals. Sci Transl Med. 2021;13:eabf7517. doi:10.1126/scitranslmed.abf7517</Citation></Reference><Reference><Citation>Augustin M, Schommers P, Stecher M, et&#xa0;al. Post-COVID syndrome in non-hospitalised patients with COVID-19: a longitudinal prospective cohort study. Lancet Reg Health Eur. 2021;6:100122. doi:10.1016/j.lanepe.2021.100122</Citation></Reference><Reference><Citation>Gerhards C, Thiaucourt M, Kittel M, et&#xa0;al. Longitudinal assessment of anti-SARS-CoV-2 antibody dynamics and clinical features following convalescence from a COVID-19 infection. Int J Infect Dis. 2021;107:221-227. doi:10.1016/j.ijid.2021.04.080</Citation></Reference><Reference><Citation>Ozonoff A, Schaenman J, Jayavelu ND, et&#xa0;al. Phenotypes of disease severity in a cohort of hospitalized COVID-19 patients: results from the IMPACC study. EBioMedicine. 2022;83:104208. doi:10.1016/j.ebiom.2022.104208</Citation></Reference><Reference><Citation>Peghin M, Palese A, Venturini M, et&#xa0;al. Post-COVID-19 symptoms 6 months after acute infection among hospitalized and non-hospitalized patients. Clin Microbiol Infect. 2021;27(10):1507-1513. doi:10.1016/j.cmi.2021.05.033</Citation></Reference><Reference><Citation>Peghin M, Martino MD, Palese A, et&#xa0;al. Post-COVID-19 syndrome and humoral response association after 1 year in vaccinated and unvaccinated patients. Clin Microbiol Infect. 2022;28(8):1140-1148. doi:10.1016/j.cmi.2022.03.016</Citation></Reference><Reference><Citation>Peluso MJ, Deitchman AN, Torres L, et&#xa0;al. Long-term SARS-CoV-2-specific immune and inflammatory responses in individuals recovering from COVID-19 with and without post-acute symptoms. Cell Rep. 2021;36(6):109518. doi:10.1016/j.celrep.2021.109518</Citation></Reference><Reference><Citation>Peluso MJ, Lu S, Tang AF, et&#xa0;al. Markers of immune activation and inflammation in individuals with Postacute sequelae of severe acute respiratory syndrome coronavirus 2 infection. J Infect Dis. 2021;224(11):1839-1848. doi:10.1093/infdis/jiab490</Citation></Reference><Reference><Citation>Pilmis B, Elkaibi I, de Ponfilly GP, et&#xa0;al. Evolution of anti-SARS-CoV-2 immune response in a cohort of French healthcare workers followed for 7 months. Infect Dis Now. 2022;52(2):68-74. doi:10.1016/j.idnow.2022.01.004</Citation></Reference><Reference><Citation>See&#xdf;le J, Waterboer T, Hippchen T, et&#xa0;al. Persistent symptoms in adult patients 1 year after coronavirus disease 2019 (COVID-19): a prospective cohort study. Clin Infect Dis. 2022;74(7):1191-1198. doi:10.1093/cid/ciab611</Citation></Reference><Reference><Citation>Sneller MC, Liang CJ, Marques AR, et&#xa0;al. A longitudinal study of COVID-19 sequelae and immunity: baseline findings. Ann Intern Med. 2022;175:969-979. doi:10.7326/M21-4905</Citation></Reference><Reference><Citation>Sonnweber T, Tymoszuk P, Sahanic S, et&#xa0;al. Investigating phenotypes of pulmonary COVID-19 recovery: a longitudinal observational prospective multicenter trial. Elife. 2022;11:e72500. doi:10.7554/eLife.72500</Citation></Reference><Reference><Citation>Wynberg E, Han AX, Boyd A, et&#xa0;al. The effect of SARS-CoV-2 vaccination on post-acute sequelae of COVID-19 (PASC): a prospective cohort study. Vaccine. 2022;40(32):4424-4431. doi:10.1016/j.vaccine.2022.05.090</Citation></Reference><Reference><Citation>Zhan Y, Zhu Y, Wang S, et&#xa0;al. SARS-CoV-2 immunity and functional recovery of COVID-19 patients 1-year after infection. Sig Transduct Target Ther. 2021;6(1):368. doi:10.1038/s41392-021-00777-z</Citation></Reference><Reference><Citation>Peluso MJ, Sans HM, Forman CA, et&#xa0;al. Plasma markers of neurologic injury and inflammation in people with self-reported neurologic postacute sequelae of SARS-CoV-2 infection. Neurol Neuroimmunol Neuroinflamm. 2022;9(5):e200003. doi:10.1212/NXI.0000000000200003</Citation></Reference><Reference><Citation>Horton DB, Barrett ES, Roy J, et&#xa0;al. Determinants and dynamics of SARS-CoV-2 infection in a diverse population: 6-month evaluation of a prospective cohort study. J Infect Dis. 2021;224(8):1345-1356. doi:10.1093/infdis/jiab411</Citation></Reference><Reference><Citation>Jia X, Cao S, Lee AS, et&#xa0;al. Anti-nucleocapsid antibody levels and pulmonary comorbid conditions are linked to post-COVID-19 syndrome. JCI Insight. 2022;7(13):156713. doi:10.1172/jci.insight.156713</Citation></Reference><Reference><Citation>Garc&#xed;a-Abell&#xe1;n J, Padilla S, Fern&#xe1;ndez-Gonz&#xe1;lez M, et&#xa0;al. Antibody response to SARS-CoV-2 is associated with long-term clinical outcome in patients with COVID-19: a longitudinal study. J Clin Immunol. 2021;41(7):1490-1501. doi:10.1007/s10875-021-01083-7</Citation></Reference><Reference><Citation>Anaya JM, Rojas M, Salinas ML, et&#xa0;al. Post-COVID syndrome. A case series and comprehensive review. Autoimmun Rev. 2021;20(11):102947. doi:10.1016/j.autrev.2021.102947</Citation></Reference><Reference><Citation>Wahlgren C, Divanoglou A, Larsson M, et&#xa0;al. Rehabilitation needs following COVID-19: five-month post-discharge clinical follow-up of individuals with concerning self-reported symptoms. eClinicalMedicine. 2022;43:101219. doi:10.1016/j.eclinm.2021.101219</Citation></Reference><Reference><Citation>Lier J, Stoll K, Obrig H, et&#xa0;al. Neuropsychiatric phenotype of post COVID-19 syndrome in non-hospitalized patients. Front Neurol. 2022;13:988359. doi:10.3389/fneur.2022.988359</Citation></Reference><Reference><Citation>Blomberg B, Mohn KGI, Brokstad KA, et&#xa0;al. Long COVID in a prospective cohort of home-isolated patients. Nat Med. 2021;27(9):1607-1613. doi:10.1038/s41591-021-01433-3</Citation></Reference><Reference><Citation>Molnar T, Varnai R, Schranz D, et&#xa0;al. Severe fatigue and memory impairment are associated with lower serum level of anti-SARS-CoV-2 antibodies in patients with Post-COVID symptoms. J Clin Med. 2021;10(19):4337. doi:10.3390/jcm10194337</Citation></Reference><Reference><Citation>Durstenfeld MS, Peluso MJ, Kelly JD, et&#xa0;al. Role of antibodies, inflammatory markers, and echocardiographic findings in postacute cardiopulmonary symptoms after SARS-CoV-2 infection. JCI Insight. 2022;7(10):e157053. doi:10.1172/jci.insight.157053</Citation></Reference><Reference><Citation>Stavileci B, &#xd6;zdemir E, &#xd6;zdemir B, Ereren E, Cengiz M. De-novo development of fragmented QRS during a six-month follow-up period in patients with COVID-19 disease and its cardiac effects. J Electrocardiol. 2022;72:44-48. doi:10.1016/j.jelectrocard.2022.02.012</Citation></Reference><Reference><Citation>Post N, Eddy D, Huntley C, et&#xa0;al. Antibody response to SARS-CoV-2 infection in humans: a systematic review. PloS One. 2020;15(12):e0244126. doi:10.1371/journal.pone.0244126</Citation></Reference><Reference><Citation>Winichakoon P, Wipasa J, Chawansuntati K, et&#xa0;al. Diagnostic performance between in-house and commercial SARS-CoV-2 serological immunoassays including binding-specific antibody and surrogate virus neutralization test (sVNT). Sci Rep. 2023;13(1):34. doi:10.1038/s41598-022-26202-1</Citation></Reference><Reference><Citation>Bayarri-Olmos R, Idorn M, Rosbjerg A, et&#xa0;al. SARS-CoV-2 neutralizing antibody responses towards full-length spike protein and the receptor-binding domain. J Immunol. 2021;207(3):878-887. doi:10.4049/jimmunol.2100272</Citation></Reference><Reference><Citation>Egger AE, Sahanic S, Gleiss A, et&#xa0;al. One-year follow-up of COVID-19 patients indicates substantial assay-dependent differences in the kinetics of SARS-CoV-2 antibodies. Microbiol Spectr. 2022;10:e0059722. doi:10.1128/spectrum.00597-22</Citation></Reference><Reference><Citation>Torres Ortiz A, Fenn Torrente F, Twigg A, et&#xa0;al. The influence of time on the sensitivity of SARS-CoV-2 serological testing. Sci Rep. 2022;12(1):10517. doi:10.1038/s41598-022-14351-2</Citation></Reference><Reference><Citation>Zheng X, Duan R h, Gong F, et&#xa0;al. Accuracy of serological tests for COVID-19: a systematic review and meta-analysis. Front Public Health. 2022;10:923525. doi:10.3389/fpubh.2022.923525</Citation></Reference><Reference><Citation>Charlton CL, Kanji JN, Tran V, et&#xa0;al. On behalf of the Canadian public health laboratory network (CPHLN) serology working group. Practical guidance for clinical laboratories for SARS-CoV-2 serology testing. Commun Dis Rep. 2021;47(4):171-183. doi:10.14745/ccdr.v47i04a01</Citation></Reference><Reference><Citation>Arkhipova-Jenkins I, Helfand M, Armstrong C, et&#xa0;al. Antibody response after SARS-CoV-2 infection and implications for immunity. Ann Intern Med. 2021;16:811-821. doi:10.7326/M20-7547</Citation></Reference><Reference><Citation>Knies A, Ladage D, Braun RJ, Kimpel J, Schneider M. Persistence of humoral response upon SARS-CoV-2 infection. Rev Med Virol. 2022;32(2):e2272. doi:10.1002/rmv.2272</Citation></Reference><Reference><Citation>Karger AB, Brien JD, Christen JM, et&#xa0;al. The serological sciences network (SeroNet) for COVID-19: depth and breadth of serology assays and plans for assay harmonization. mSphere. 2022;7:e0019322. doi:10.1128/msphere.00193-22</Citation></Reference><Reference><Citation>Chivese T, Matizanadzo JT, Musa OAH, et&#xa0;al. The prevalence of adaptive immunity to COVID-19 and reinfection after recovery - a comprehensive systematic review and meta-analysis. Pathog Glob Health. 2022;116:269-281. doi:10.1080/20477724.2022.2029301</Citation></Reference><Reference><Citation>Elslande JV, Oyaert M, Lorent N, et&#xa0;al. Lower persistence of anti-nucleocapsid compared to anti-spike antibodies up to one year after SARS-CoV-2 infection. Diagn Microbiol Infect Dis. 2022;103(1):115659. doi:10.1016/j.diagmicrobio.2022.115659</Citation></Reference><Reference><Citation>Van den Hoogen LL, Smits G, van Hagen CCE, et&#xa0;al. Seropositivity to nucleoprotein to detect mild and asymptomatic SARS-CoV-2 infections: a complementary tool to detect breakthrough infections after COVID-19 vaccination? Vaccine. 2022;40(15):2251-2257. doi:10.1016/j.vaccine.2022.03.009</Citation></Reference><Reference><Citation>Knezevic I, Mattiuzzo G, Page M, et&#xa0;al. WHO international standard for evaluation of the antibody response to COVID-19 vaccines: call for urgent action by the scientific community. Lancet Microb. 2022;3(3):e235-e240. doi:10.1016/S2666-5247(21)00266-4</Citation></Reference><Reference><Citation>Whitaker HJ, Gower C, Otter AD, et&#xa0;al. Nucleocapsid antibody positivity as a marker of past SARS-CoV-2 infection in population serosurveillance studies: impact of variant, vaccination, and choice of assay cut-off. medRxiv. 2021. doi:10.1101/2021.10.25.21264964</Citation></Reference><Reference><Citation>Steenhuis M, Wouters E, Schrezenmeier H, et&#xa0;al. Quality assessment and harmonization of laboratories across Europe for multiple SARS-CoV-2 serology assays. Vox Sanguinis. 2023;118:666-673. doi:10.1111/vox.13480</Citation></Reference><Reference><Citation>Basharat S, Chao YS, McGill SC. Subtypes of Post-COVID-19 condition: a review of the emerging evidence. CJHT. 2022;2(12):7-22. doi:10.51731/cjht.2022.516</Citation></Reference><Reference><Citation>Canas LS, Molteni E, Deng J, et&#xa0;al. Profiling post-COVID-19 condition across different variants of SARS-CoV-2: a prospective longitudinal study in unvaccinated wild-type, unvaccinated alpha-variant, and vaccinated delta-variant populations. Lancet Digital Health. 2023;5(7):e421-e434. doi:10.1016/S2589-7500(23)00056-0</Citation></Reference><Reference><Citation>Sancilio A, Schrock JM, Demonbreun AR, et&#xa0;al. COVID-19 symptom severity predicts neutralizing antibody activity in a community-based serological study. Sci Rep. 2022;12(1):12269. doi:10.1038/s41598-022-15791-6</Citation></Reference><Reference><Citation>Yaugel-Novoa M, Bourlet T, Paul S. Role of the humoral immune response during COVID-19: guilty or not guilty? Mucosal Immunol. 2022;15(6):1170-1180. doi:10.1038/s41385-022-00569-w</Citation></Reference><Reference><Citation>Wong MCS, Huang J, Wong YY, et&#xa0;al. Epidemiology, symptomatology, and risk factors for long COVID symptoms: population-based, multicenter study. JMIR Public Health Surveill. 2023;9(1):e42315. doi:10.2196/42315</Citation></Reference><Reference><Citation>Jacobsen EM, Fabricius D, Class M, et&#xa0;al. High antibody levels and reduced cellular response in children up to one year after SARS-CoV-2 infection. Nat Commun. 2022;13(1):7315. doi:10.1038/s41467-022-35055-1</Citation></Reference><Reference><Citation>Morello R, Martino L, Buonsenso D. Diagnosis and management of post-COVID (long COVID) in children: a moving target. Curr Opin Pediatr. 2023;35(2):184-192. doi:10.1097/MOP.0000000000001221</Citation></Reference><Reference><Citation>D&#xed;az-Salazar S, Navas R, Sainz-Maza L, et&#xa0;al. Blood group O is associated with post-COVID-19 syndrome in outpatients with a low comorbidity index. Infect Dis. 2022;27:897-908. doi:10.1080/23744235.2022.2115548</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>